Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEPW) Gains from Investment Securities (2021 - 2025)

Coeptis Therapeutics Holdings has reported Gains from Investment Securities over the past 5 years, most recently at $1.3 million for Q4 2025.

  • Quarterly results put Gains from Investment Securities at $1.3 million for Q4 2025, up 147.02% from a year ago — trailing twelve months through Dec 2025 was $1.3 million (up 147.02% YoY), and the annual figure for FY2025 was $1.3 million, changed.
  • Gains from Investment Securities for Q4 2025 was $1.3 million at Coeptis Therapeutics Holdings, up from $539660.0 in the prior quarter.
  • Over the last five years, Gains from Investment Securities for COEPW hit a ceiling of $16.8 million in Q4 2021 and a floor of -$14.2 million in Q1 2021.
  • Median Gains from Investment Securities over the past 5 years was $539660.0 (2024), compared with a mean of $286781.0.
  • Biggest five-year swings in Gains from Investment Securities: plummeted 136.31% in 2022 and later skyrocketed 343.25% in 2023.
  • Coeptis Therapeutics Holdings' Gains from Investment Securities stood at $16.8 million in 2021, then tumbled by 100.89% to -$150000.0 in 2022, then surged by 1071.67% to $1.5 million in 2023, then plummeted by 62.97% to $539660.0 in 2024, then surged by 147.02% to $1.3 million in 2025.
  • The last three reported values for Gains from Investment Securities were $1.3 million (Q4 2025), $539660.0 (Q4 2024), and $1.5 million (Q2 2023) per Business Quant data.